PREVALENCE OF HIGH-RISK HUMAN PAPILLOMAVIRUS INFECTION AMONG WOMEN ATTENDING GYNECOLOGICAL EXAMINATIONS AT CAN THO GYNECOLOGY AND OBSTETRICS HOSPITAL IN 2025-2026
Main Article Content
Abstract
Background: Cervical cancer is one of the most common malignancies among women, with high-risk human papillomavirus (HPV) infection recognized as the primary etiological factor. Determining the prevalence and genotype distribution of high-risk HPV at the local level is essential for developing effective screening and prevention strategies. Objectives: To determine the prevalence and genotype distribution of high-risk HPV among women attending gynecological examinations at Can Tho Gynecology and Obstetrics Hospital in 2025–2026. Materials and methods: A cross-sectional descriptive study was conducted on 1,200 women aged 21-65 years who attended gynecological examinations from October 2025 to March 2026. Cervical specimens were tested for high-risk HPV using genotype Real-time PCR on the Cobas® 4800 system. Results: The prevalence of high-risk HPV infection was 11.2% (134/1,200). Among high-risk HPV-positive cases, the group of 12 high-risk HPV types other than HPV 16 and HPV 18 was the most prevalent (59.0%), followed by HPV 16 (18.7%), HPV 18 (9.7%), HPV 16 + group of 12 high-risk HPV types (8.2%), HPV 18 + group of 12 high-risk HPV types (3.7%), and HPV 16 + HPV 18 + group of 12 high-risk HPV types (0.7%). Conclusion: The prevalence of high-risk HPV infection among women attending gynecological examinations at Can Tho Gynecology and Obstetrics Hospital was 11.2%, with a predominance of the 12 high-risk HPV types other than HPV 16 and HPV 18. These findings highlight the need to maintain and expand routine HPV screening programs for effective cervical cancer prevention.
Keywords
HPV, high-risk HPV, cervical cancer
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
References
2. International Agency for Research on Cancer. IARC Handbooks of Cancer Prevention: Cervical Cancer Screening. 2022. https://publications.iarc.fr/604.
3. Lê Trung Tín, Nguyễn Hồng Phong. Giá trị tầm soát ung thư cổ tử cung bằng phối hợp phương pháp Cyprep Pap Test và xét nghiệm HPV Realtime PCR ở phụ nữ khám phụ khoa tại Bệnh Viện Quốc Tế Phương Châu năm 2021-2022. Tạp chí Y Dược học Cần Thơ. 2022. 51, 155-162, doi: 10.58490/ctump.2022i51.325.
4. Sharipova I P, Musabaev E I, Sadirova S S, Suyarkulova D T, Tahev S E, et al. Prevalence of high-risk human papillomavirus genotypes among women in Uzbekistan, 2021–2023. J Gynecol Oncol. 2025. 36 (1), e7, doi: 10.3802/jgo.2025.36.e7.
5. Nguyễn Thu Hằng, Hà Hải Bằng, Đào Ngọc Tuấn, Chu Thị Hồng Quyên, Nguyễn Kim Huệ và cộng sự. Khảo sát tình hình nhiễm Human Papillomavirus và sự phân bố các type nguy cơ cao ở phụ nữ đến khám phụ khoa tại Bệnh Viện A Thái Nguyên. Tạp chí Y Dược học Quân sự. 2025. 50 (1), 46-52, doi:10.56535/jmpm.v50i1.944.
6. Lintao R C V, Cando L F T, Perias G A S, Tantengco O A G, Tabios I K B, et al, (2022). Current Status of Human Papillomavirus Infection and Cervical Cancer in the Philippines. Frontiers in Medicine . 2022. 9, 1-15, doi: 10.3389/fmed.2022.929062.
7. Hassani S, Nadji P S, Mohseni A, Farzami M R, Samiee S M, et al. Evaluation Frequency of Human Papillomavirus and Its Related Genotypes in Women of the General Population Living in 11 Provinces of Iran. Canadian Journal of Infectious Diseases and Medical Microbiology. 2022. 2022, 1-8, doi: 10.1155/2022/8668557.
8. Nguyễn Quỳnh Anh, Vũ Huy Lượng, Nguyễn Thị Hà Vinh, Phạm Quỳnh Hoa, Lê Huyền My và cộng sự. Tình hình nhiễm Human Papillomavirus tại Bệnh Viện Da Liễu Trung Ương năm 2023. Tạp chí Y học Việt Nam. 2024. 539 (1), 386-390, doi:10.51298/vmj.v539i1.9771.
9. Nguyễn Duy Ánh. Nghiên cứu tỷ lệ nhiễm lậu cầu, Chlamydia trachomatis và HPV ở phụ nữ trong độ tuổi sinh đẻ tại Bệnh viện Phụ sản Hà Nội bằng kỹ thuật realtime PCR. Tạp Chí Y Dược lâm sàng 108 . 2022. 17(2), 81-88, doi: 10.52389/ydls.v17i2.1154.